26.07.2011 • News

Solutia Q2 Profit Rises

Solutia Monday reported second-quarter net income attributable to the company of $68 million or $0.56 per share, compared to $41 million or $0.34 per share last year.

Adjusted earnings for the quarter increased to $69 million or $0.57 per share, compared to $53 million or $0.44 per share in the prior year period. On average, six analysts polled by Thomson Reuters expected earnings of $0.56 per share for the quarter. Analysts' estimates typically exclude special items.

Net sales for the quarter grew 8% to $543 million from $502 million in the same period last year. Looking forward, the company maintained its adjusted earnings guidance range of $2.10 to $2.25 for the full year. Analysts currently expect $2.21 per share for the full year.

 

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.